Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
MRKR Stock Chart & Stats
$1.37
-$0.17(-5.70%)
At close: 4:00 PM EST
$1.37
-$0.17(-5.70%)
Day’s Range― - ―
52-Week Range$0.81 - $4.07
Previous CloseN/A
Volume39.59K
Average Volume (3M)282.04K
Market Cap
$23.34M
Enterprise Value-$2.80M
Total Cash (Recent Filing)$17.59M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Mar 12, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding16,673,126
10 Day Avg. Volume127,297
30 Day Avg. Volume282,041
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.50
Price to Sales (P/S)4.24
P/FCF Ratio-2.56
Enterprise Value/Market Cap-0.12
Enterprise Value/Revenue-0.60
Enterprise Value/Gross Profit0.36
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$9.00Price Target Upside556.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$2.68M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And PersistencePhase 1/2 data showing meaningful tumor responses and persistent in vivo expansion of infused MAR-T cells supports the potential for MT-601 to provide durable benefit in hard-to-treat tumors.
Combination Therapy And Tumor PenetrationCombining MAR-T cells with standard chemotherapy appeared to enhance tumor penetration without adding toxicity, indicating a viable strategy to improve response rates when used alongside established regimens.
Regulatory Approval ProspectsAnalyst expects an accelerated approval pathway for MT-601 in DLBCL given encouraging efficacy in a high unmet-need population and a favorable safety profile that regulators often prioritize.
Bears Say
Clinical Development RiskSignificant clinical development uncertainty remains, as pivotal trials could yield inconclusive results or fail to meet endpoints, delaying or undermining value realization.
Commercialization, Reimbursement And FundingCommercialization challenges and uncertain reimbursement, combined with potential needs for additional capital, could constrain launch execution and pressure shareholder value.
Competitive LandscapeIntense competition from other emerging immunotherapies targeting similar indications could limit market uptake and pricing power even if MT-601 reaches approval.
Marker Therapeutics News
MRKR FAQ
What was Marker Therapeutics Inc’s price range in the past 12 months?
Marker Therapeutics Inc lowest stock price was $0.81 and its highest was $4.07 in the past 12 months.
What is Marker Therapeutics Inc’s market cap?
Marker Therapeutics Inc’s market cap is $23.34M.
When is Marker Therapeutics Inc’s upcoming earnings report date?
Marker Therapeutics Inc’s upcoming earnings report date is Mar 12, 2026 which is in 8 days.
How were Marker Therapeutics Inc’s earnings last quarter?
Marker Therapeutics Inc released its earnings results on Nov 14, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.24.
Is Marker Therapeutics Inc overvalued?
According to Wall Street analysts Marker Therapeutics Inc’s price is currently Undervalued.
Does Marker Therapeutics Inc pay dividends?
Marker Therapeutics Inc does not currently pay dividends.
What is Marker Therapeutics Inc’s EPS estimate?
Marker Therapeutics Inc’s EPS estimate is -0.19.
How many shares outstanding does Marker Therapeutics Inc have?
Marker Therapeutics Inc has 16,673,126 shares outstanding.
What happened to Marker Therapeutics Inc’s price movement after its last earnings report?
Marker Therapeutics Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went up 3.371%.
Which hedge fund is a major shareholder of Marker Therapeutics Inc?
Currently, no hedge funds are holding shares in MRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
MRKR Stock 12 Month Forecast
Average Price Target
$9.00
▲(556.93% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
18.09%
Insiders
2.09% Mutual Funds
5.81% Other Institutional Investors
72.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---